Phase 1/2 × INDUSTRY × Lymphoma, Follicular × Clear all
NCT03162536 2025-09-08

ARQ 531-101

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Phase 1/2 Active not recruiting
190 enrolled
NCT03997968 2024-12-24

A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

Cyteir Therapeutics, Inc.

Phase 1/2 Completed
169 enrolled
NCT00002663 2023-02-13

Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies

Atara Biotherapeutics

Phase 1/2 Completed
58 enrolled 18 charts
NCT01474681 2020-12-30

Safety and Tolerability of HSC835 in Patients With Hematological Malignancies

Novartis

Phase 1/2 Completed
27 enrolled 15 charts